Showing results (191-200 of 241) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2021
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 AntibodyJames J Harding, Victor Moreno, Yung-Jue Bang, et al.
NPJ Precision Oncology|April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignanciesOmar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Med (New York, N.Y.)|June 28, 2025
Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancersSteven H Lin, Vivek Subbiah, Evan N Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicDenis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Cancer Discovery|October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationDavid S Hong, Van K Morris, Badi El Osta, et al.
Pageof 25